Interpretation of “An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline:Treatment of Drug-Resistant Tuberculosis” and comparison with “Guideline for Chemotherapy of Drug Resistant Tuberculosis(2019)” in China

doi:10.3969/j.issn.1000-6621.2020.01.005

Abstract

Abstract:

To interpret the “Treatment of Drug-resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline (ATS Guideline)”, including the drugs, formulating treatment regimen and duration, as well as treatment of isoniazid-resistant TB, preventive therapy of close contacts of MDR-TB; and then to compared “ATS Guideline” with “Guideline for Chemotherapy of Drug Resistant Tuberculosis (2019)” in China.

Key words: Tuberculosis,multidrug-resistant, Drug therapy,combination, Program evaluation, Comment, Guideline

LIU Yi-dian,GUI Xu-wei,SHEN Xiao-na,YU Yuan-yuan,YAO Lan,LOU Hai,SHA Wei,XIAO He-ping. Interpretation of “An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline:Treatment of Drug-Resistant Tuberculosis” and comparison with “Guideline for Chemotherapy of Drug Resistant Tuberculosis(2019)” in China[J]. Chinese Journal of Antituberculosis, 2020, 42(1): 12-16. doi: 10.3969/j.issn.1000-6621.2020.01.005

References 14

[1]	Nahid P, Mase SR, Migliori GB , et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med, 2019,200(10):e93-142. doi: 10.1164/rccm.201909-1874ST URL pmid: 31729908
[2]	中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019,41(10):1025-1073.
[3]	中国防痨协会. 耐药结核病化学治疗指南(2019年). 北京: 人民卫生出版社, 2019.
[4]	中国防痨协会. 耐药结核病化学治疗指南(2015). 中国防痨杂志, 2015,37(5):421-469.
[5]	World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2019. doi: 10.4103/ijmr.IJMR_579_19 URL pmid: 31249191
[6]	刘宇红 . 注射类抗结核药物在我国耐药结核病治疗中的作用. 中华结核和呼吸杂志, 2019,42(6):401-404.
[7]	U.S. Food and Drug Administration. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs. Washington DC: FDA, 2019 [2019-09-23].
[8]	《中国防痨杂志》编辑委员会, 中国医疗保健国际交流促进会结核病防治分会基础学组和临床学组. 结核分枝杆菌耐药性检测专家共识. 中国防痨杂志, 2019,41(2):129-137.
[9]	World Health Organization. Intent tuberculosis infection: Updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018.
[10]	World Health Organization. Global tuberculosis report 2019. Geneva:World Health Organization, 2019. doi: 10.9745/GHSP-D-19-00210 URL pmid: 31852741
[11]	肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识. 中华风湿病学杂志, 2013,17(8):508-512.
[12]	中华医学会感染病学分会艾滋病学组, 中华医学会热带病与寄生虫学分会艾滋病学组. HIV合并结核分枝杆菌感染诊治专家共识. 中华临床感染病杂志, 2017,10(2):81-90.
[13]	中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 肺结核基层诊疗指南(2018年). 中华全科医师杂志, 2019,18(8):709-717.
[14]	高磊, 金奇 . 关口前移:结核潜伏感染及其控制. 中国防痨杂志, 2018,40(8):791-795.

[1]	Duan Hongfei, Tao Yong. Interpretation of social organization standard of Diagnosis Specification of Intraocular Tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 258-261.
[2]	Wu Qian, Wang Wei, Zhang Yu, Chen Songhua, Chen Bin. Construction of an evaluation indicator system for Zero Tuberculosis Community in Zhejiang Province [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 331-337.
[3]	Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Inspire-CODA Research Group. Expert consensus on the treatment of tuberculosis with contezolid [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 123-129.
[4]	Zhao Yanli, Che Nanying. Interpretation of social organization standard of Specification for Pathological Diagnosis of Tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(4): 371-374.
[5]	Ming Wenhua, Ma Tingting, Wang Hongtian, Wang Xueyan. Aspirin-exacerbated respiratory diseases: pathogenesis and treatment strategies [J]. Chinese Journal of Antituberculosis, 2024, 46(11): 1400-1405.
[6]	Sha Wei. Significance and challenges of the implementation of PAN-TB treatment strategy for tuberculosis prevention and control [J]. Chinese Journal of Antituberculosis, 2024, 46(10): 1188-1192.
[7]	Fu Liang, Ren Tantan, Zhang Peize, Lu Shuihua. Interpretation of WHO consolidated guidelines on tuberculosis, Module 4: treatment-drug-resistant tuberculosis treatment, 2022 update [J]. Chinese Journal of Antituberculosis, 2023, 45(4): 336-348.
[8]	Ge Qiping, Zhang Lijie, Huang Xuerui, Jiang Guanglu, Han Xiqin, Wang Jingping, Du Jian, Ma Yan, Gao Weiwei. Effect of a new treatment regimen on patients with initially retreated drug-sensitive pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2023, 45(11): 1078-1083.
[9]	Gao Dan, Wang Linghua, Huang Jinpeng, Zhang Yue, Mao Xiaoxiao. Analysis of the application effect of integrated traditional Chinese and Western medicine pulmonary rehabilitation nursing program for patients with tuberculous empyema undergoing thoracoscopic clearance [J]. Chinese Journal of Antituberculosis, 2023, 45(10): 940-948.
[10]	AN Hui-ru, WU Xue-qiong. Interpretation of immunoadjuvant therapy in Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 Edition) [J]. Chinese Journal of Antituberculosis, 2022, 44(6): 539-543.
[11]	TIAN Xiao-mei, LEI Juan, LIU Jing, LIU Guang-tian, PAN Li, LIU Tao, SHI Feng, WANG Xiao-lin. Analysis on the effect of diagnosis and treatment management of rifampicin-resistant pulmonary tuberculosis and financing mode in Ningxia [J]. Chinese Journal of Antituberculosis, 2021, 43(8): 772-777.
[12]	LIU Zheng-wei, PENG Ying, ZHANG Ming-wu, ZHANG Yu, CHEN Song-hua, CHEN Bin, WANG Xiao-meng. Analysis of the efficiency of tuberculosis diagnosis progress based on GeneXpert MTB/RIF application in Zhejiang Province [J]. Chinese Journal of Antituberculosis, 2021, 43(8): 790-795.
[13]	CHEN Hui, ZHANG Hui, CHENG Jun. Interpretation of the Chinese Guidelines for Prevention and Control of Tuberculosis in Schools [J]. Chinese Journal of Antituberculosis, 2021, 43(6): 542-545.
[14]	LIU Er-yong, LI Yu-hong, ZHOU Lin, ZHAO Yan-lin. Making panoramic plan:extra-pulmonary tuberculosis needs to be integrated into the national tuberculosis program [J]. Chinese Journal of Antituberculosis, 2021, 43(5): 428-431.
[15]	MA Yan*, GAO Wei-wei. Pay attention to the reasonable treatment of retreatment tuberculosis:today is not what it used to be [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 313-317.